Browse the evidence

Incretin-based therapies (liraglutide, semaglutide, tirzepatide) produce significant body weight reduction (≥5% in majority of patients) and reduce the 10-year relative risk of type 2 diabetes development by 60-69% in individuals with obesity.

If you have obesity or overweight with related health issues, incretin-based medications (like semaglutide or tirzepatide) are highly effective for significant weight loss and preventing type 2 diabetes. They work by mimicking hormones that regulate appetite and are taken weekly (or daily for liraglutide) alongside lifestyle changes. These are not quick fixes but long-term treatments requiring continuous use to maintain results.

Tirzepatide demonstrates superior body weight reduction compared to semaglutide 2.4 mg and liraglutide 3.0 mg in non-diabetic subjects with obesity.

Among incretin therapies, tirzepatide offers the greatest weight loss potential for non-diabetic individuals with obesity, outperforming semaglutide and liraglutide.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces superior body weight reduction and glycemic control compared to semaglutide, insulin degludec, and insulin glargine in patients with type 2 diabetes.

For patients with Type 2 Diabetes struggling with weight and blood sugar, Tirzepatide offers a once-weekly injection that has been shown to be more effective than semaglutide, insulin degludec, and insulin glargine in reducing both body weight and HbA1c. Treatment starts at a low dose (2.5 mg) and is titrated up to 5, 10, or 15 mg weekly to manage side effects. This therapy is particularly beneficial for those who have not achieved targets with oral medications or other injectables.

Tirzepatide promotes significant body weight loss in non-diabetic adults with obesity, with efficacy increasing with dose (5, 10, 15 mg).

For individuals with obesity who do not have Type 2 Diabetes, Tirzepatide is an approved once-weekly injection that has been shown to produce significant and clinically meaningful weight loss over 72 weeks. The medication is titrated starting at 2.5 mg and increased to 5, 10, or 15 mg weekly. It also improves blood pressure, waist circumference, and lipid profiles.

Subcutaneous semaglutide (0.5 mg and 1.0 mg) significantly reduces HbA1c and body weight in Type 2 Diabetes patients compared to placebo and other antidiabetic agents.

If you have Type 2 Diabetes, once-weekly subcutaneous semaglutide (0.5 mg or 1.0 mg) is a highly effective treatment for lowering blood sugar (HbA1c) and reducing body weight. It works better than many other standard diabetes medications and placebo. Be prepared for potential nausea or diarrhea, which are common but often mild and decrease over time.

Semaglutide (2.4 mg/weekly) significantly reduces the risk of major adverse cardiovascular events (MACE) in patients with overweight or obesity without diabetes, while also producing substantial weight loss and improving heart failure symptoms in those with preserved ejection fraction.

If you have heart disease or high risk for it, along with excess weight, semaglutide (Ozempic/Wegovy) is a highly effective treatment. It is taken as a once-weekly injection, starting at a low dose and increasing over 4 months to 2.4 mg. It significantly lowers your risk of heart attack and stroke, helps you lose about 9-13% of your body weight, and improves heart failure symptoms if you have them. Common side effects like nausea are usually temporary and manageable.

Tirzepatide (5-15 mg weekly) significantly reduces body weight and HbA1c in patients with Type 2 Diabetes and obesity, outperforming semaglutide, insulin degludec, and insulin glargine.

Tirzepatide is a once-weekly injection for T2DM and obesity that works by mimicking gut hormones (GIP and GLP-1) to improve insulin sensitivity and reduce appetite. It produces greater weight loss and blood sugar control than existing GLP-1 drugs like semaglutide or insulin. Start with a low dose to manage side effects, titrating up every few weeks.

High-dose GLP-1 receptor agonists (semaglutide 2.4 mg/week) and dual GLP-1/GIP agonists (tirzepatide 15 mg/week) produce substantial weight loss (>15% and >20% respectively) in non-diabetic obese individuals, with efficacy maintained over 2 years.

For non-diabetic individuals with obesity, weekly injections of semaglutide (2.4 mg) or tirzepatide (15 mg), combined with a reduced-calorie diet and exercise, can lead to 15-20% body weight loss over two years. Expect initial gastrointestinal side effects like nausea, which usually subside within a few months as the dose is gradually increased.

GLP-1 receptor agonists (GLP-1RAs) such as semaglutide and liraglutide produce significant weight loss and improve cardiovascular outcomes by acting as incretin mimetics that target G-protein-coupled receptors to regulate body fat and energy balance.

GLP-1 medications like semaglutide are highly effective for significant weight loss (approx. 15%) when combined with a reduced-calorie diet. They work by mimicking gut hormones to reduce appetite and slow digestion. Treatment requires weekly injections and gradual dose escalation to manage side effects like nausea. Because obesity is chronic, long-term use is often necessary to maintain results.

Tirzepatide, a dual GIP and GLP-1 receptor agonist, produces superior weight loss compared to semaglutide and other comparators in patients with type 2 diabetes and obesity.

Tirzepatide is a dual-acting hormone medication (GIP/GLP-1) that offers even greater weight loss than semaglutide (up to 21% in trials). It is administered as a once-weekly injection, starting at a low dose and increasing every 4 weeks. It is particularly effective for patients with type 2 diabetes and obesity, improving both blood sugar and weight significantly more than other comparators.

A pragmatic prescribing pathway for liraglutide 3.0 mg using multiple stopping rules (≥5% weight loss at 16 weeks, ≥10% at 32 weeks, and ≥15% at 52 weeks) significantly increases the proportion of adults with obesity achieving ≥15% weight loss compared to standard specialist weight management services alone.

If you have a BMI of 35 or higher and conditions like high blood pressure or sleep apnea, ask your doctor about a specialized weight management program that includes liraglutide 3.0 mg. This medication is taken as a daily injection, starting at a low dose and increasing to 3 mg. A key part of this approach is 'stopping rules': if you don't lose enough weight at specific check-ups, the medication is stopped to save costs and avoid unnecessary side effects. This method helps ensure that only those who benefit continue treatment, leading to much better long-term weight loss results than lifestyle changes alone.

Combining GLP-1 RAs with basal insulin provides superior glycemic management and cardiorenal protection compared to using either therapy alone, while mitigating the side effects of high-dose GLP-1 RAs.

If you are struggling to control your blood sugar with just a GLP-1 shot (like Ozempic) or just basal insulin, combining them is often the most effective strategy. New 'fixed-ratio' combination pens allow you to inject both medications in a single shot. This approach lowers your A1C more effectively than either drug alone, protects your heart and kidneys, and often reduces the side effects (like nausea) associated with high doses of GLP-1 RAs.

GLP-1 receptor agonists (GLP1-RA) and SGLT2 inhibitors (SGLT2-i) are effective interventions for obesity-related cardiometabolic complications by reducing body weight and addressing pathophysiological derangements.

If lifestyle changes are insufficient, discuss GLP-1 RAs or SGLT2 inhibitors with your doctor. These medications are now recognized as essential tools for managing obesity and its heart/kidney risks, not just for diabetes.

GLP-1 receptor agonists (GLP-1RAs) such as semaglutide and liraglutide induce significant weight loss (up to ~15%) in non-diabetic individuals with obesity, primarily by acting on GLP-1 receptors in the brain (specifically the arcuate nucleus and area postrema) to suppress food intake.

GLP-1 receptor agonists like semaglutide (2.4 mg weekly) are highly effective for weight loss in obese, non-diabetic adults, achieving ~15% body weight reduction. They work by suppressing appetite via brain receptors. Be aware of common side effects like nausea and the likelihood of weight regain if treatment stops, suggesting a need for long-term management.

Dual GIP/GLP-1 receptor agonists (e.g., tirzepatide) produce greater weight loss than GLP-1RAs alone (e.g., semaglutide) in both diabetic and non-diabetic populations, while potentially reducing nausea through GIP receptor signaling.

Tirzepatide (5-15 mg weekly) is more effective for weight loss than semaglutide in patients with type 2 diabetes, achieving 8.5-12.4% weight loss compared to 6.7% for semaglutide. It works by targeting both GIP and GLP-1 receptors, potentially offering a better side effect profile regarding nausea.

Subcutaneous semaglutide at 2.4 mg once weekly produces clinically significant weight loss (mean 14.9–17.4% reduction) in adults with obesity or overweight, with gastrointestinal side effects being the primary limiting factor.

For adults with obesity, weekly subcutaneous semaglutide (2.4 mg) combined with lifestyle changes leads to substantial weight loss (approx. 15%). The main barrier is gastrointestinal side effects like nausea, which are usually mild and do not prevent weight loss. If injections are not preferred, oral semaglutide is an alternative, though subcutaneous administration may yield slightly greater weight loss.

Subcutaneous semaglutide (0.5-1.0 mg) and oral semaglutide (14 mg) effectively reduce body weight and HbA1c in patients with Type 2 Diabetes, with subcutaneous administration showing greater weight loss than oral administration in indirect comparisons.

For patients with Type 2 Diabetes, both subcutaneous (0.5-1.0 mg weekly) and oral (14 mg daily) semaglutide effectively reduce weight and blood sugar. Subcutaneous administration appears to produce greater weight loss than the oral form, though both are superior to other diabetes medications.

Tirzepatide (a dual GIP/GLP-1 receptor agonist) facilitates the largest reduction in body weight and increases in health-related quality of life (QoL) among Type 2 Diabetes medications.

If weight loss and quality of life are your primary goals, Tirzepatide is the most effective medication identified in this analysis. It offers greater weight reduction and QoL improvements than standard GLP-1 RAs, though it may cause gastrointestinal side effects.

GLP-1 receptor agonists (GLP-1RA) such as semaglutide and liraglutide produce significant weight loss (≥10%) and cardiovascular benefits in adults with obesity.

GLP-1 receptor agonists like semaglutide are highly effective for weight loss, often achieving 10% or more body weight reduction, and also provide cardiovascular benefits. These medications are available in both injectable and oral forms, offering flexibility for long-term management of obesity.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces substantial, dose-dependent weight loss in adults with obesity (mean 15-21% over 72 weeks) and superior glycemic control compared to placebo and other GLP-1 agonists.

Tirzepatide is a once-weekly injection that targets two gut hormones (GIP and GLP-1) to reduce appetite and improve blood sugar. In clinical trials, it led to an average weight loss of 15-21% over 72 weeks, significantly outperforming placebo and other GLP-1 drugs like Semaglutide. It is prescribed for adults with obesity (BMI ≥30, or ≥27 with comorbidities) and requires a slow dose escalation to manage gastrointestinal side effects.

GLP-1 and GIP agonists (e.g., semaglutide) significantly improve glycemic control, promote weight loss, and provide cardiovascular and renal protection in patients with obesity and type 2 diabetes.

If you have obesity and type 2 diabetes, ask your doctor about GLP-1/GIP agonists. These drugs treat the underlying biology, help you lose weight, and protect your heart and kidneys.

Semaglutide 2.4 mg administered once weekly via subcutaneous injection significantly reduces body weight in adults with obesity or overweight when used as an adjunct to lifestyle modifications.

If you have obesity or overweight with a related health condition, ask your doctor about Semaglutide 2.4 mg. It is taken as a once-weekly injection alongside diet and exercise. Expect significant weight loss (around 15% in trials), but be prepared for temporary stomach issues like nausea, which usually get better over time.

GLP-1 receptor agonists (e.g., liraglutide, semaglutide) and SGLT2 inhibitors provide cardiovascular and renal benefits independent of glycemic control, with GLP-1 RAs being preferred for obesity/T2D and SGLT2 inhibitors for T2D with heart failure.

If you have T2D and obesity, ask your doctor about GLP-1 agonists (like Semaglutide or Liraglutide). They help with weight loss and protect your heart and kidneys, even if your blood sugar is already controlled. If you also have heart failure, SGLT2 inhibitors might be better.

GLP-1 receptor agonists lower plasma glucose and suppress appetite, providing significant benefits for glycemic control and weight loss in type 2 diabetes and obesity.

If you have type 2 diabetes or obesity, GLP-1 receptor agonists are a proven, first-line treatment option that effectively lowers blood sugar and aids weight loss. Discuss these options with your healthcare provider to see if they are appropriate for your specific health profile.